NCPD Article

Screening, Prevention, Detection, and Treatment of Cancer Therapy-Induced Bone Loss in Patients With Breast Cancer

Connie E. Limburg

Screening, prevention, detection, cancer treatment-induced bone loss
ONF 2007, 34(1), 55-63. DOI: 10.1188/07.ONF.55-63

Purpose/Objectives: To identify protocols to screen, detect, prevent, and treat cancer therapy-induced bone loss resulting in osteoporosis in patients with breast cancer.

Data Sources: Published books and articles.

Data Synthesis: Normal bone remodeling is affected by hormonal stimulation. Breast cancer therapies target hormones that promote cancer cell growth. Chemotherapy regimens and hormone ablation may cause ovarian failure, resulting in decreased hormone levels. A decrease in hormones, in estrogen- and progesterone-positive and -negative patients, introduces an environment for decreased bone remodeling, which may result in thinning bone and osteoporosis. The acceleration of bone loss leading to osteoporosis can result in higher fracture rates among breast cancer survivors.

Conclusions: With proper use of screening tools, patient education, and advice about lifestyle changes, all prior to cancer treatment, healthcare professionals may decrease or prevent bone loss in patients with breast cancer. Doing so minimizes healthcare costs and decreases morbidity and mortality rates in breast cancer survivors.

Implications for Nursing: As more individuals diagnosed with breast cancer are surviving for extended periods of time, oncology nurses are providing long-term follow-up care. Part of the care should include proper screening and patient education for healthier recovery and prevention of further healthcare complications as a result of cancer treatment.

Jump to a section


    American Cancer Society. (2006). Breast cancer facts and figures 2005-2006. Retrieved December 5, 2006, from

    Bines, J., Oleske, D., & Cobleigh, M. (1996). Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. Journal of Clinical Oncology, 14, 1718-1729. (2006). Tamoxifen. Retrieved December 5, 2006, from

    Cann, C., Martin, M., Genant, H., & Jaffe, R. (1984). Decreased spinal mineral content in amenorrheic women. JAMA, 251, 626-629.

    Chen, Z., Maricic, M., Bassford, T., Pettinger, M., Ritenbaugh, C., Lopez, A., et al. (2005). Fracture risk among breast cancer survivors: Results from the Women's Health Initiative Observational Study. Archives of Internal Medicine, 165, 552-558.

    Coleman, R. (2004). Hormone- and chemotherapy-induced bone loss in breast cancer. Oncology, 18(Suppl. 5), 16-20.

    Coombes, R., Hall, E., Gibson, L., Paridaens, R., Jassem, J., Delozier, T., et al. (2004). A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. New England Journal of Medicine, 350, 1081-1092.

    Daniel, H., Dunn, S., Ferguson, D., Lomas, G., Niazi, Z., & Stratte, P. (2000). Progressive osteoporosis during androgen deprivation therapy for prostate cancer. Journal of Urology, 163, 181-186.

    Daniell, H.W. (1997). Osteoporosis after orchiectomy for prostate cancer. Journal of Urology, 157, 439-444.

    Gross, G., Ott, C., Lindsey, A., Twiss, J., & Waltman, N. (2002). Postmenopausal breast cancer survivors at risk for osteoporosis: Physical activity, vigor, and vitality. Oncology Nursing Forum, 29, 1295-1300.

    Hawkins, B., Campos, M., & Fessele, K. (2005). Got bones? It takes more than milk to preserve skeletal health in oncology patients. Pittsburgh, PA: Oncology Nursing Society.

    Hillner, B., Ingle, J., Chlebowski, R., Gralow, J., Yee, G., Janjan, N., et al. (2003). American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. Journal of Clinical Oncology, 21, 4042-4057.

    International Osteoporosis Foundation. (2002). Osteoporosis in the workplace. The social, economic, and human costs of osteoporosis on employees, employers, and government. Liege, Belgium: Author.

    Kanis, J. (2002). Diagnosis of osteoporosis and assessment of fracture risk. Lancet, 359, 1929-1936.

    Kowalak, J.P., Cavallini, M., Chohan, N.D., Hughes, A.S., Johnson, P.H., Poeggel, J.C. (Eds). (2001). Handbook of pathophysiology. Springhouse, PA: Springhouse Corporation.

    Maillefert, J., Sibilia, J., Michel, F., Saussine, C., Javier, R., & Tavernier, C. (1999). Bone mineral density in men treated with synthetic gonadotropinreleasing hormone agonists for prostatic carcinoma. Journal of Urology, 161, 1219-1222.

    Maxwell, C., & Viale, P. (2005). Cancer treatment-induced bone loss in patients with breast or prostate cancer. Oncology Nursing Forum, 32, 589-603.

    Merck & Co., Inc. (2006). Breast cancer. Retrieved April 30, 2006, from

    Mincey, B., Moraghan, T., & Perez, E. (2000). Prevention and treatment of osteoporosis in women with breast cancer. Mayo Clinic Proceedings, 75, 821-829.

    National Cancer Institute. (2004). Aromatase inhibitors. Retrieved June 26, 2005, from

    National Institute of Arthritis. (2005). What breast cancer survivors need to know about osteoporosis. Retrieved December 6, 2006, from

    National Institutes of Health. (n.d.). NIH osteoporosis and related bone diseases—National Resource Center. Retrieved June 27, 2005, from

    National Institutes of Health. (2000, October 4). More from the osteoporosis consensus. Retrieved June 20, 2005, from

    National Institutes of Health. (2006). Osteoporosis overview. Retrieved December 5, 2006, from

    National Osteoporosis Foundation. (2006). Prevention. Retrieved June 26, 2005, from

    Otto, S.E. (2001). Oncology nursing (4th ed.). St. Louis, MO: Mosby.

    Perry, C., & Figgitt, D. (2004). Zoledronic acid: A review of its use in patients with advanced cancer. Drugs, 64, 1197-1211.

    Pfeilschifter, J., & Diel, I. (2000). Osteoporosis due to cancer treatment: Pathogenesis and management. Journal of Clinical Oncology, 18, 1570-1593.

    Powles, T., Hickish, T., Kanis, J., Tidy, A., & Ashley, S. (1996). Effect of tamoxifen on bone mineral density measured by dual-engery x-ray absorptiometry in healthy premenopausal and postmenopausal women. Journal of Clinical Oncology, 14, 78-84.

    Ramaswamy, B., & Shapiro, C. (2003). Osteopenia and osteoporosis in women with breast cancer. Seminars in Oncology, 30, 763-775.

    Ravdin, P. (2004). Managing the risk of osteoporosis in women with a history of early breast cancer. Oncology, 18, 1385-1390, 1393.

    Rosen, L. (2004). New generation of bisphosphonates: Broad clinical utility in breast and prostate cancer. Oncology, 18(Suppl. 5), 26-32.

    Ross, R., & Small, E. (2002). Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. Journal of Urology, 167, 1952-1956.

    Saarto, T., Blomqvist, C., Valimaki, M., Sarna, S., & Elomaa, I. (1997). Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: A randomized study in premenopausal breast cancer patients. Journal of Clinical Oncology, 15, 1341-1347.

    Shapiro, C., Manola, J., & Leboff, M. (2001). Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. Journal of Clinical Oncology, 19, 3303-3305.

    U.S. Department of Health and Human Services. (2004). Bone health and osteoporosis: A report of the surgeon general. Retrieved June 21, 2005, from